Jilin Zhengye Biological Products Co., Ltd. (Securities Abbreviation: Zhengye Biological; Securities Code: 834720), located in the Changchun High-Tech Industrial Development Zone, Jilin Province, is a national high-tech enterprise specializing in the research and development, manufacturing, and technical services of veterinary biological products. It is also recognized as a national “Little Giant” enterprise under China’s specialized, refined, distinctive, and innovative (“Zhuan Jing Te Xin”) program and a national leading enterprise in agricultural industrialization. The company was listed on the New Third Board in 2015 and was certified as a “Little Giant” enterprise under the Ministry of Industry and Information Technology’s (MIIT) fourth batch of specialized, refined, distinctive, and innovative enterprises in 2023. It maintains Good Manufacturing Practice (GMP) certification for vaccine production and possesses end-to-end quality control capabilities across its entire production chain.  

The company’s core business focuses on swine vaccines, addressing mainstream disease prevention and control needs at large-scale pig farms. Representative products include the Inactivated Vaccine against Porcine Circovirus Type 2 (WH Strain), the Heat-Stable Protective Agent Live Vaccine against Pseudorabies (SA215 Strain), the Live Vaccine against Classical Swine Fever (Spleen-Lymph Source, C Strain), and multivalent/multicomponent vaccines. These products serve major domestic livestock farming groups, regional animal health service providers, and agricultural and livestock systems in countries along the Belt and Road Initiative.  

Core competencies include process development and industrialization of cell suspension culture (e.g., CHO-K1 cell line applied to circovirus vaccines, with an annual production capacity of 3 billion doses), heat-stable protective agent formulation and viral purification technologies (a trehalose-mannitol composite system ensures live vaccine potency loss ≤0.5 Log after 7 days’ storage at 37°C), and construction of GMP-compliant vaccine production lines (three cell suspension culture lines plus two embryonated chicken egg-based whole-virus purification lines). Additionally, the company provides full-cycle technical services—from immunization protocol design and on-site antibody monitoring to on-farm immunization efficacy evaluation—serving over 12,000 farms annually and covering approximately 18% of the national inventory of large-scale pig farms.  

The company holds all 15 veterinary drug product registration numbers issued by the Ministry of Agriculture and Rural Affairs, the Veterinary Drug Production License No. (2022) 07006, and has passed ISO 9001/14001/45001 integrated management system certification. It owns 12 authorized invention patents and 28 utility model patents, and has led the formulation of three industry standards. Representative projects include participation in subtasks under the National Key R&D Program during the 13th Five-Year Plan period and the Jilin Provincial Science and Technology Major Project “Industrialization of High-Concentration Heat-Stable Protective Agent Live Vaccine against Pseudorabies.” Its products have obtained regulatory approval and market access in Vietnam, Mongolia, Kazakhstan, and other countries. Export revenue reached RMB 28.6 million in 2025, representing a year-on-year growth of 31.2%. Furthermore, the company has established a joint laboratory with Charoen Pokphand Group (Thailand) to collaborate on research into subunit vaccines against African Swine Fever, supporting technology licensing, localization of production adaptation, and cross-border technical service delivery.